Vacuette z serum sep clot activator tubes

Eleven prospectively collected invasive epithelial OC samples (HGS, n = 8; low grade serous, n = 1; endometrioid, n = 1; mucinous, n = 1; mean age = 54.7 years), one benign tumor (papillary serous cystadenoma; age = 86 years), 18 non-neoplastic tissue samples (breast, n = 7 and adnexal, n = 11; mean age = 60.2 years), two non-neoplastic endometrial tissues (mean age = 68 years), and 23 WBC samples (breast cancer patients, n = 10 and OC patients, n = 13 [11 of which match corresponding OC tissue samples, one matches corresponding normal endometrial sample, and one matches normal ovarian sample]; mean age = 57.8 years) were assessed by RRBS. All samples were collected prospectively at the University College London Hospital in London and the Charles University Hospital in Prague.
For serum sets 1–3 and the NACT serum set, women attending the University College London Hospital in London and the Charles University Hospital in Prague were invited, a written consent obtained, and 20–40 mL blood taken (VACUETTE® Z Serum Sep Clot Activator tubes, Cat. 455071, Greiner Bio One International GmbH), centrifuged at 3000 rpm for 10 min with serum stored at – 80 °C.

Rabbit inoculations and blood sampling were performed at University of Stellenbosch Animal Research Facility in accordance with requirements, guidelines and approval of the University of Cape Town and University of Stellenbosch Animal Ethics Committees (AEC 015-51). Two groups of five female New Zealand White rabbits were used to compare the immunogenicity of the gp140-Zera^® and Zera^®-gp140 proteins. Forty to 50 μg protein diluted in 1x PBS to a final volume of 500 μl, was administered into the quadricep muscle of the hind leg of each rabbit on day 0 and subsequently at weeks 4, 12, and 20 post initial immunization. Blood samples were collected into VACUETTE^® Z Serum Sep Clot Activator tubes (Greiner Bio-One) at weeks 0, 4, 8, 12, 14, 16, 20, and 22 post vaccination.